University of Kentucky, College of Public Health, Lexington, KY, USA.
Respir Res. 2011 Oct 12;12(1):136. doi: 10.1186/1465-9921-12-136.
Chronic obstructive pulmonary disease (COPD) is supposed to be classified on the basis of post-bronchodilator lung function. Most longitudinal studies of COPD, though, do not have post-bronchodilator lung function available. We used pre-and post bronchodilator lung function data from the Lung Health Study to determine whether these measures differ in their ability to predict mortality.
We limited our analysis to subjects who were of black or white race, on whom we had complete data, and who participated at either the 1 year or the 5 year follow-up visit. We classified subjects based on their baseline lung function, according to COPD Classification criteria using both pre- and post-bronchodilator lung function. We conducted a survival analysis and logistic regression predicting death and controlling for age, sex, race, treatment group, smoking status, and measures of lung function (either pre- or post-bronchodilator. We calculated hazard ratios (HR) with 95% confidence intervals (CI) and also calculated area under the curve for the logistic regression models.
By year 15 of the study, 721 of the original 5,887 study subjects had died. In the year 1 sample survival models, a higher FEV1 % predicted lower mortality in both the pre-bronchodilator (HR 0.87, 95% CI 0.81, 0.94 per 10% increase) and post-bronchodilator (HR 0.84, 95% CI 0.77, 0.90) models. The area under the curve for the respective models was 69.2% and 69.4%. Similarly, using categories, when compared to people with "normal" lung function, subjects with Stage 3 or 4 disease had similar mortality in both the pre- (HR 1.51, 95% CI 0.75, 3.03) and post-bronchodilator (HR 1.45, 95% CI 0.41, 5.15) models. In the year 5 sample, when a larger proportion of subjects had Stage 3 or 4 disease (6.4% in the pre-bronchodilator group), mortality was significantly increased in both the pre- (HR 2.68, 95% CI 1.51, 4.75) and post-bronchodilator (HR 2.46, 95% CI 1.63, 3.73) models.
Both pre- and post-bronchodilator lung function predicted mortality in this analysis with a similar degree of accuracy. Post-bronchodilator lung function may not be needed in population studies that predict long-term outcomes.
慢性阻塞性肺疾病(COPD)应根据支气管扩张剂后肺功能进行分类。然而,大多数 COPD 的纵向研究并没有支气管扩张剂后肺功能的资料。我们使用来自肺健康研究的支气管扩张剂前后肺功能数据,来确定这些指标在预测死亡率方面的能力是否存在差异。
我们将分析仅限于黑人和白人种族的受试者,他们有完整的数据,并且在第 1 年或第 5 年随访时参加了研究。我们根据他们的基线肺功能,根据 COPD 分类标准,使用支气管扩张剂前后的肺功能进行分类。我们进行了生存分析和逻辑回归预测死亡,并控制年龄、性别、种族、治疗组、吸烟状况以及肺功能指标(支气管扩张剂前后)。我们计算了危险比(HR)和 95%置信区间(CI),并计算了逻辑回归模型的曲线下面积。
在研究的第 15 年,5887 名研究对象中有 721 人死亡。在第 1 年的生存模型中,FEV1%预计值越高,支气管扩张剂前后模型的死亡率越低(支气管扩张剂前:HR 0.87,95%CI 0.81,0.94,每增加 10%;支气管扩张剂后:HR 0.84,95%CI 0.77,0.90)。各自模型的曲线下面积分别为 69.2%和 69.4%。同样,使用分类方法,与“正常”肺功能的人相比,3 或 4 期疾病的患者在支气管扩张剂前后模型中具有相似的死亡率(支气管扩张剂前:HR 1.51,95%CI 0.75,3.03;支气管扩张剂后:HR 1.45,95%CI 0.41,5.15)。在第 5 年的样本中,当更多的患者患有 3 或 4 期疾病(支气管扩张剂前组的 6.4%)时,在支气管扩张剂前后模型中,死亡率均显著增加(支气管扩张剂前:HR 2.68,95%CI 1.51,4.75;支气管扩张剂后:HR 2.46,95%CI 1.63,3.73)。
在这项分析中,支气管扩张剂前后的肺功能都能以相似的准确性预测死亡率。在预测长期结果的人群研究中,可能不需要支气管扩张剂后的肺功能。